BASOPENIA INDUCTION BY VINORELBINE ALONE AND IN COMBINATION WITH DOXORUBICIN AND CISPLATIN IN CANCER PATIENTS

Abstract

The anticancer drugs used in cancer therapy exerts cure along with deleterious effects. They bring structural and physiological changes in vital organs. Basopenia or basocytopenia is one of the major side effects of antineoplastic agents. This study therefore aimed to investigate the alterations in basophile count in cancer patients administered vinorelbine, cisplatine and doxorubicin as part of their chemotherapy protocols. The pharmacovigilance study or post marketing therapeutical monitoring become important when the drugs are part of certain cancer chemotherapy plans. A total 60 adult patients were randomly divided in to two groups; Group-1 received the Vinorelbine alone and group 2 patients on Vinorelbine base combinations. Results showed significantly lower potential of basopenia in the patients on vinorelbine alone (p value 0.435) vinorelbine base combinations (p value 0.437). The comparison of mean values of these two groups at every week indicated no difference of the chance of basopenia (p values Week 0-4: 0.517, 0.089, 0.434, 0.475 and 0.275). Similarly no significant difference was observed in the basophile count before therapy and after therapy (at week-4) in both of the groups ((p value for G-1: 0.221 and G-2: 0.314). However, among the groups, the potential for induction of basopenia is similar. Thus; in conclusion, there is no significant difference in the overall basopenia in both of the chemotherapy protocols. The clinical oncologist and consultant physician can select either of the treatment plan